Trial Profile
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Erectile dysfunction; Interstitial cystitis; Overactive bladder
- Focus Pharmacodynamics
- 01 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2026.
- 01 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 30 Sep 2026.
- 22 Dec 2020 Planned End Date changed from 1 Oct 2021 to 30 Sep 2022.